503155759 01/28/2015 PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2

EPAS ID: PAT3202372

SUBMISSION TYPE:		NEW ASSIGNMENT	
NATURE OF CONVEYANCE:		ASSIGNMENT	
CONVEYING PARTY DA	ATA		
		Name	Execution Date
GENAERA LIQUIDATING	G TRUST		08/21/2009
RECEIVING PARTY DA	ТА		
Name:	OHR PH	ARMACEUTICAL, INC.	
Street Address:	489 5TH	AVENUE, 28TH FLOOR	
City:	NEW YO	RK	
State/Country:	NEW YO	RK	
Postal Code:	10017		
PROPERTY NUMBERS	Total: 1		
Property Type		Number	
Patent Number:	65	596712	
CORRESPONDENCE D			
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i>	(2 e sent to t provided;	02)739-3001 he e-mail address first; if that is unsuccessful if that is unsuccessful, it will be sent via US M	
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone:	2) e sent to t provided; 20	02)739-3001 he e-mail address first; if that is unsuccessful if that is unsuccessful, it will be sent via US M 02-739-3000	
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email:	2) e sent to t provided; 20 pa	02)739-3001 he e-mail address first; if that is unsuccessful if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com	
Fax Number: <i>Correspondence will be using a fax number, if p</i> Phone: Email: Correspondent Name:	2) e sent to t provided; 20 pa G	02)739-3001 he e-mail address first; if that is unsuccessful if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com REGORY T. LOWEN	
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email:	(2 e sent to t provided; 20 pa G 11	02)739-3001 he e-mail address first; if that is unsuccessful if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com	
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1:	(2 e sent to t provided; 2(pa G 11 W	02)739-3001 he e-mail address first; if that is unsuccessful if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com REGORY T. LOWEN 111 PENNSYLVANIA AVENUE, NW	
Fax Number: <i>Correspondence will be using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4:	(2 e sent to t provided; 2(pa G 11 W	02)739-3001 he e-mail address first; if that is unsuccessful if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com REGORY T. LOWEN 111 PENNSYLVANIA AVENUE, NW ASHINGTON, D.C. 20004	
Fax Number: <i>Correspondence will be using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4:	(2 e sent to t provided; 2(pa G 11 W	02)739-3001 he e-mail address first; if that is unsuccessful, if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com REGORY T. LOWEN 111 PENNSYLVANIA AVENUE, NW ASHINGTON, D.C. 20004 001216-5002-04 GREGORY T. LOWEN	
Fax Number: <i>Correspondence will be using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4: ATTORNEY DOCKET NU	(2 e sent to t provided; 2(pa G 11 W	02)739-3001 he e-mail address first; if that is unsuccessful if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com REGORY T. LOWEN 111 PENNSYLVANIA AVENUE, NW VASHINGTON, D.C. 20004 001216-5002-04	
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4: ATTORNEY DOCKET NU AME OF SUBMITTER: BIGNATURE:	(2 e sent to t provided; 2(pa G 11 W	02)739-3001 he e-mail address first; if that is unsuccessful, if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com REGORY T. LOWEN 111 PENNSYLVANIA AVENUE, NW ASHINGTON, D.C. 20004 001216-5002-04 GREGORY T. LOWEN /Gregory T. Lowen/	
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4: ATTORNEY DOCKET NUME ATTORNEY ATTORNEY DOCKET NUME ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY ATTORNEY AT	(2 e sent to t provided; 20 pa 30 11 W	02)739-3001 he e-mail address first; if that is unsuccessful, if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com REGORY T. LOWEN 111 PENNSYLVANIA AVENUE, NW ASHINGTON, D.C. 20004 001216-5002-04 GREGORY T. LOWEN /Gregory T. Lowen/ 01/28/2015	
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4: ATTORNEY DOCKET NU VAME OF SUBMITTER: BIGNATURE: DATE SIGNED: Total Attachments: 17	(2 e sent to t provided; 20 pa 30 11 W IMBER:	02)739-3001 he e-mail address first; if that is unsuccessful, if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com REGORY T. LOWEN 111 PENNSYLVANIA AVENUE, NW ASHINGTON, D.C. 20004 001216-5002-04 GREGORY T. LOWEN /Gregory T. Lowen/ 01/28/2015 tingTrust-Ohr#page1.tif	
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4: Address Line 4: ATTORNEY DOCKET NU AME OF SUBMITTER: SIGNATURE: DATE SIGNED: Total Attachments: 17 source=Assignment-Gena source=Assignment-Gena	(2 e sent to t provided; 20 pa 30 11 W IMBER: IMBER: eraLiquida eraLiquida eraLiquida	02)739-3001 he e-mail address first; if that is unsuccessful, if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com REGORY T. LOWEN 111 PENNSYLVANIA AVENUE, NW ASHINGTON, D.C. 20004 001216-5002-04 GREGORY T. LOWEN /Gregory T. Lowen/ 01/28/2015 ttingTrust-Ohr#page1.tif ttingTrust-Ohr#page2.tif ttingTrust-Ohr#page3.tif	
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4: Address Line 4: ATTORNEY DOCKET NU NAME OF SUBMITTER: SIGNATURE: DATE SIGNED: Total Attachments: 17 source=Assignment-Gena source=Assignment-Gena source=Assignment-Gena	(2 e sent to t provided; 20 pa 30 11 W IMBER: IMBER: eraLiquida eraLiquida eraLiquida eraLiquida	02)739-3001 he e-mail address first; if that is unsuccessful, if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com REGORY T. LOWEN 111 PENNSYLVANIA AVENUE, NW ASHINGTON, D.C. 20004 001216-5002-04 001216-5002-04 GREGORY T. LOWEN /Gregory T. Lowen/ 01/28/2015 ttingTrust-Ohr#page1.tif ttingTrust-Ohr#page2.tif ttingTrust-Ohr#page3.tif ttingTrust-Ohr#page4.tif	
Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4: Address Line 4: ATTORNEY DOCKET NU AME OF SUBMITTER: SIGNATURE: DATE SIGNED: Total Attachments: 17 source=Assignment-Gena source=Assignment-Gena	(2 e sent to t provided; 20 pa 30 11 W UMBER: UMBER: UMBER: UMBER: UMBER: UMBER: UMBER: UMBER: UMBER:	02)739-3001 he e-mail address first; if that is unsuccessful, if that is unsuccessful, it will be sent via US M 02-739-3000 atents@morganlewis.com REGORY T. LOWEN 111 PENNSYLVANIA AVENUE, NW ASHINGTON, D.C. 20004 001216-5002-04 GREGORY T. LOWEN /Gregory T. Lowen/ 01/28/2015 tingTrust-Ohr#page1.tif tingTrust-Ohr#page2.tif tingTrust-Ohr#page3.tif tingTrust-Ohr#page4.tif tingTrust-Ohr#page5.tif	

source=Assignment-GenaeraLiquidatingTrust-Ohr#page7.tif
source=Assignment-GenaeraLiquidatingTrust-Ohr#page8.tif
source=Assignment-GenaeraLiquidatingTrust-Ohr#page9.tif
source=Assignment-GenaeraLiquidatingTrust-Ohr#page10.tif
source=Assignment-GenaeraLiquidatingTrust-Ohr#page11.tif
source=Assignment-GenaeraLiquidatingTrust-Ohr#page12.tif
source=Assignment-GenaeraLiquidatingTrust-Ohr#page13.tif
source=Assignment-GenaeraLiquidatingTrust-Ohr#page14.tif
source=Assignment-GenaeraLiquidatingTrust-Ohr#page15.tif
source=Assignment-GenaeraLiquidatingTrust-Ohr#page16.tif
source=Assignment-GenaeraLiquidatingTrust-Ohr#page17.tif

ASSIGNMENT OF PATENTS

THIS ASSIGNMENT is made as of this 21st day of August, 2009, by Genaera Liquidating Trust ("Assignor") in favor of Ohr Pharmaceutical, Inc., a Delaware corporation (formerly BBM Holdings, Inc., "Ohr").

<u>RECITALS</u>

A. Reference is made to that certain Asset Purchase Agreement, dated as of August 21, 2009 (the "Asset Purchase Agreement"), by and between Ohr, as Purchaser, and Assignor, as Seller.

B. The terms defined in the Asset Purchase Agreement and not otherwise defined herein shall have the meanings given them in the Asset Purchase Agreement;

C. Assignor is assigning its entire right, title and interest in and to the Patents, Patent Licenses and patent applications listed on <u>Schedule A</u>, attached hereto, and to the inventions described and claimed in those Patents, Patent Licenses and patent applications.

<u>ASSIGNMENT</u>

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby sell, transfer, and assign to Ohr, its successors, assigns and legal representatives, all of the rights, title and interests in and to the Patents, Patent Licenses and patent applications, including without limitation, all Patents which may be granted on any of the aforesaid patent applications, the worldwide rights to the inventions described and claimed therein, and reissues, re-examinations, divisions, continuations, renewals, extensions and continuations-in-part therefor throughout the world, together with all rights under the International Convention for the Protection of Industrial Property and any similar treaties or agreements, the same to be held and enjoyed by Ohr for its own use and benefit and the use and benefit of its successors, assigns and legal representatives, as fully and entirely as the same would have been held and enjoyed by Assignor had this Assignment not been made, together with all income, royalties, damages and payments resulting from or attributable to activity or conduct after the effective date of this Assignment, and the right to sue and collect for all future, present and past infringements thereof, together with all causes of action for any and all infringements which may have occurred prior to the execution of this Assignment and the right to receive and retain the proceeds relating to those infringements. Ohr shall have the right to obtain and hold in its name all patents, registrations and similar protection throughout the world which may be available in the Patents, Patent Licenses and patent applications.

Assignor agrees: (a) to execute (i) all necessary papers throughout the world to be used in connection with the Patents, Patent Licenses and patent applications and any reissues, re-

PATENT REEL: 034835 FRAME: 0440

examinations, divisions, continuations, renewals, extensions and continuations-in-part therefor, as Ohr may deem necessary or expedient, (ii) all papers in connection with any interference, legal or other proceedings throughout the world to maintain, protect or enforce, or otherwise relating to, the Patents, Patent Licenses and Patent Applications or any reissues, divisions, continuations, renewals, extensions and continuations-in-part therefor, and (iii) all papers and documents which may be necessary throughout the world in connection with the preparation and filing of any foreign applications or with making claims to priority rights granted under the provisions of the International Convention for Protection of Industrial Property or similar agreements; (b) to cooperate with Ohr in every way reasonably possible in obtaining evidence and going forward in any such proceedings throughout the world; and (c) to perform all other affirmative acts which in Ohr's reasonable discretion may be necessary or desirable throughout the world to maintain, protect or enforce the Patents, Patent Licenses, and patent applications and any reissues, divisions, continuations, renewals, extensions and continuations-in-part therefor. These obligations of assistance by Assignor shall survive closing under the Asset Purchase Agreement and shall continue for so long as Ohr may require such assistance from Assignor.

This Assignment includes the right, where such right can be legally exercised by Ohr, in its own name, to apply for and obtain patents in countries foreign to the United States of America, including the full right to claim for any such applications the benefits of the International Convention for Protection of Industrial Property or similar agreements, as fully and entirely as Assignor could have done if the applications has been filed in its name, and the entire interest in any patents which may be granted on any such applications in such foreign countries.

Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks of the United States, and the appropriate officials in any other country, to issue any and all Letters Patent that may be granted upon any patent application or any reissues, divisions, continuations, renewals, extensions and continuations-in-part therefor covered by this Assignment to Ohr, its successors and assigns.

Assignor hereby covenants and warrants that no other agreement has been or will be executed in conflict herewith.

Assignor hereby grants to both Ohr and the law firm of Hahn & Hessen LLP of New York, New York (and any other law firm designated by Hahn & Hessen LLP), authority and power to insert on this instrument any further information which may be necessary or desirable for identifying any of the Patents for purposes of recordation in the United States Patent and Trademark Office or any similar or comparable office or officials of any foreign country.

[rest of page intentionally left blank]

IN WITNESS WHEREOF this Assignment has been duly executed by an authorized officer of Assignor and is effective as of the date first above written.

GENAERA LIQUIDATING TRUST, Assignor

By: Argyce LLC, Trystee By: John Skolas

Name. Title: President

OHR PHARMACEUTICAL, INC.

By:

Name: Andrew Limpert Title:President

Signature Page - Assignment of Palents

IN WITNESS WHEREOF this Assignment has been duly executed by an authorized officer of Assignor and is effective as of the date first above written.

GENAERA LIQUIDATING TRUST, Assignor

By: Argyce LLC, Trustee

By:		
Name:	John Skolas	
Title:	President	

OHR PHARMACEUTICAL, INC. By: Name: Andrew Limper Title: President

SCHEDULE A

Squalamine, Trodusquamine and Analogues Patents

Our File: Patent No.: Issue Date: Serial No.: Filing Date: Title: Inventors: Status: Expiration Date:	5,192,756 3/9/93 853,634 3/18/92 AMINOSTER Michael Zas Issued	23)(036870-5 ROL ANTIBIO loff, Karen Mc	TIC	ınne Wehrli
Expiration Date: Foreign Cases:	3/18/2012 <u>Country</u> PTC PTC EPO EPO* Australia Australia Canada Canada	<u>Status</u> Filed Filed Issued Filed Issued Filed Issued	Date 2/10/93 9/30/93 2/10/93 4/23/97 2/10/93 2/20/97 2/10/93 4/17/07	<u>Serial/Patent No.</u> US93/01187 WO 9318773 93905856.6 EP 0 637 243 36619/93 675782 2,130,803 2,130,803
	Japan	Filed	2/10/93	516544/1993
*EPO Countries:	Japan AT, BE, CH/ SE	Issued LI, DE, DK, E	5/27/02 S, FR, GB, GI	3,286,321 R, IE, IT, LU, MC, NL, PT,
Synopsis:	This patent of	describes the n antimicrobia	•	of matter of squalamine and
Our File: Patent No.: Issue Date Serial No.: Filing Date: Title:	5,840,740 11/24/98 08/483,059 6/7/95 AMINOSTER INFECTION	USING THE	AMINOSTER	METHOD OF TREATING OL COMPOUNDS
Inventors: Status: Expiration Date:	Michael Zas Issued 11/24/2015	loff, Ann Shin	nar, William K	inney, Meena Rao
Foreign Cases:	<u>Country</u> PCT PCT Australia Australia Canada Canada	<u>Status</u> Filed Published Filed Issued Filed Issued	Date 6/7/96 US96 12/19/96 6/7/96 63349 12/14/00 6/7/96 2,223 9/16/08	WO9640728 9/96 723663

	EPO EPO EPO* EPO	Filed Published Issued Filed	6/7/96 96922 4/1/98 08320 2/11/04 6/7/96 04002	094 0832094 2943.1-1211
*EPO Countries	EPO Japan Japan S. Africa	Published Filed Issued Published	12/8/97	2307 164 96/4818
Synopsis:	PT, SE This patent of	covers the use		, GR, IE, IT, LU, MC, NL, and MSI-1361 to treat
Our File: Patent No.: Issue Date Serial No.: Filing Date: Title: ADMI Inventors: Status: Expiration Date: Foreign Cases: <i>Synopsis:</i>	NISTERING A Michael Zasl Issued 8/18/2015 See 49-01M This patent o	F INHIBITING AN AMINOST off, Ann Shini covers the use of cells (tumo	EROL COMP nar, William K e of trodusque	TION OF CELLS BY OUND Cinney, Mark Anderson Demine to inhibit the Tress the immune system
Our File: Patent No.: Issue Date: Serial No.: Filing Date: Title: ADMI Inventor: Status: Expiration Date: Foreign Cases: <i>Synopsis:</i>	NISTERING A Michael Zasl Issued 6/9/2015 See 49-01M	F TREATING A STEROID C off covers the trea		ECTION BY ral disease, including HIV
Our File: Patent No.: Issue Date:	49-05M (368 5,840,936 11/24/98	70-5045-05)		

Serial No.: Filing Date: Title: Inventors: Status: Expiration Date: Foreign Cases: <i>Synopsis:</i>	08/475,572 6/7/95 AMINOSTEROL COMPOUNDS USEFUL AS INHIBITORS OF THE SODIUM/PROTON EXCHANGER (NHE) Michael Zasloff, Ann Shinnar, Meena Rao, William Kinney Issued 6/10/2014 See 49-01M This patent covers the composition of matter for trodusquemine and MSI-1437. It has a terminal disclaimer based on the 50-01M case.				
Our File:	49-06M (36870-5045-06)				
Patent No.: Issue Date: Serial No.: Filing Date: Title: Inventor: Status: Expiration Date: Foreign Cases: <i>Synopsis:</i>	5,874,597 2/23/99 08/476,855 6/7/95 CERTAIN AMINOSTEROL COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS INCLUDING THESE COMPOUNDS Steven Jones Issued 6/10/14 See 49-01M This application covers the composition of matter for MSI-1414, 1415, 1417, 1448 and 1449. It has a terminal disclaimer based on the 50-01M case.				
Our File:	49-07M (36870-5045-07)				
Patent No.: Issue Date Serial No.: Filing Date: Title: Inventor: Status: Expiration Date: Foreign Cases:	5,792,635 8/11/98 08/474,799 6/7/95 METHOD OF INHIBITING THE SODIUM/PROTON EXCHANGER NHE AND METHOD OF INHIBITING GROWTH BY ADMINISTERING SQUALAMINE Michael Zasloff Issued 8/11/2015 <u>Country</u> <u>Status</u> <u>Date</u> <u>Serial/Patent #</u> PCT Filed 6/7/96 US96/08954 PCT Published 12/19/96 WO9640151 Australia Filed 6/7/96 61528/96 Australia Issued 11/4/99 712436 Canada Pending 6/7/96 2,223,908				

Africa *EPO Countries <i>Synopsis:</i>	PT, SE <i>This patent c</i>		6/7/96 9-501 6/15/99 2/8/08 40779 96/4819 S, FI, FR, GB e of squalamin	9096.6 0 831 837 397 11-506775	
COMPOUNI Inventor: Status: Expiration Date: Foreign Cases: Synopsis: This p	MACEUTICA DS Michael Zasl Issued 6/10/2014 See 49-01M Datent covers	MINOSTERO L COMPOSI off, Ann Shin the compositi	nar, William K ion of matter c	DS AND IDING THESE Tinney and Steven J Ion MSI-1409, 1410, Ininal disclaimer base	1416,
Our File: Patent No. Issue Date: Serial No.: Filing Date: Publication No. Publication Date Title: TREAT	2003- 01492 8/7/2003	,417 ïrst CPA-11/2 87	,	S WITH SQUALAMINE	
Inventor: Status: Expiration Date: Foreign Cases: <i>Synopsis:</i>	lssued 6/22/2015 See 49-07M <i>This patent a</i>	application co		inney and Steven J of squalamine and it e eye.	
Our File: Patent No.:	50-01M (368 5,637,691	70-5077-01)			

Issue Date: Serial No.: Filing Date: Title:	STEROID D	G THEM, AN	, PHÁRMACE	UTICAL COMPOSITIONS AS ANTIBIOTICS OR
Inventors: Status: Expiration Date:			Zasloff, Williar	n A. Kinney, Robert Moriarty
Foreign Cases:	Country PCT PCT EPO	<u>Status</u> Filed Published Filed	<u>Date</u> 3/10/94 9/15/94 3/10/94	<u>Serial/Patent No.</u> US94/02397 WO94/20520 94911470.6
	EPO EPO*	Published Issued	12/27/95 8/19/98	0 688 333 0 688 333
	Australia Australia	Filed	3/10/94 6/18/98	63974/94
	Canada	lssued Filed	6/18/98 3/10/94	692766 2,157,594
	Japan	Filed	3/10/94	06-520212
	Japan	Published	8/13/96	8-507527
	Japan	Issued	4/23/04	3546886
*EPO Countries:	AT, BE, CH/ SE	LI, DE, DK, E	S, FR, GB, GI	R, IE, IT, LU, MC, NL, PT,
Synopsis:	•	covers the col f squalamine.		natter of aminosterol
Our File:	50-03M (368	370-5077-03)		
Patent No.:	5,721,226	,		
Issue Date:	2/24/98			
Serial No.:	08/478,763 ((priority date:	3/10/93)	
Filing Date:	6/7/95			
Title:				NESIS USING EROID DERIVATIVES
Inventors:	,			n A. Kinney, Robert
inventors.	•	lwood C. Coll	-	ITA. Rinney, Robert
Status:	Issued			
Expiration Date:	2/24/2015			
Foreign Cases:	<u>Country</u>	<u>Status</u>	<u>Date</u>	<u>Serial/Patent No.</u>
-	PCT	Filed	9/13/94	US94/10265
	PCT	Published	9/14/95	WO95/24415
	EPO	Filed	9/13/94	94931274.8
	EPO*	Issued	12/5/01	0749437
	Canada	Filed	9/13/94	2,185,123
	Japan	Filed	9/13/94	07-523429
	Australia	Filed	9/13/94	80101/94
	Australia	Issued	12/24/98	700344

*EPO Countries:	AT, BE, CH/LI, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE					
Synopsis:	This patent covers a method for inhibiting angiogenesis in a patient with squalamine or a squalamine analogue.					
Our File: Patent No.: Issue Date: Serial No.: Filing Date: Title: Inventors: Status: Expiration Date: Foreign Cases:	AMINOSTER	ority date: 8/ ROL ESTER (18/94) COMPOUNDS inney, Steven <u>Date</u> 12/18/97 6/25/98			
Cana	Australia da Abano	Abandoned	2,274	57087/98		
Carla	Japan	Abandoned	2,274	10-527987		
Synopsis:			mposition of m pecifically and	natter for various generically.		
Our File:	60-12M (036	870-5080)				
Our File: Patent No.:	60-12M (036 7,074,778	870-5080)				
Patent No.: Issue Date:	7,074,778 7/11/2006					
Patent No.: Issue Date: Serial No.:	7,074,778 7/11/2006 10/148,553,	60/169,959	F 12/9/00)			
Patent No.: Issue Date:	7,074,778 7/11/2006 10/148,553,	60/169,959 led in the PC1	Г 12/9/00)			
Patent No.: Issue Date: Serial No.: Filing Date: Publication No.: Date:	7,074,778 7/11/2006 10/148,553, 12/9/99P (Fil 2003-023279 12/18/03	60/169,959 led in the PC1 91				
Patent No.: Issue Date: Serial No.: Filing Date: Publication No.: Date: Title:	7,074,778 7/11/2006 10/148,553, 12/9/99P (Fil 2003-023279 12/18/03 ASTHMA AS	60/169,959 led in the PCT 91 SSOCIATED F	-ACTORS AS	TARGETS FOR		
Patent No.: Issue Date: Serial No.: Filing Date: Publication No.: Date: Title:	7,074,778 7/11/2006 10/148,553, 12/9/99P (Fil 2003-023279 12/18/03 ASTHMA AS	60/169,959 led in the PCT 91 SSOCIATED F	-ACTORS AS	TARGETS FOR ASTHMA AND		
Patent No.: Issue Date: Serial No.: Filing Date: Publication No.: Date: Title: TREA RELATED D Inventors:	7,074,778 7/11/2006 10/148,553, 12/9/99P (Fil 2003-023279 12/18/03 ASTHMA AS ASTHMA AS	60/169,959 led in the PCT 91 SSOCIATED F C ALLERGIES	FACTORS AS S INCLUDING			
Patent No.: Issue Date: Serial No.: Filing Date: Publication No.: Date: Title: TREA RELATED D	7,074,778 7/11/2006 10/148,553, 12/9/99P (Fil 2003-023279 12/18/03 ASTHMA AS ASTHMA AS ASTHMA AS	60/169,959 led in the PCT 91 SSOCIATED F C ALLERGIES	FACTORS AS S INCLUDING	ASTHMA AND teve Jones and Bill Kinney <u>Serial/Patent No.</u> US00/33526 WO01/42273 22579/01 784795 00986312.7 349 2001-543570		

Synopsis:			12/11/00 e use of amine e IL-9 pathway	2,393,135 osteroids to treat asthma by '.
	6,147,060 11/14/2000 08/840,706 4/25/97 (pric TREATMEN BINATION W	TH OTHER A	NOMAS USIN	G SQUALAMINE IN AGENTS
Inventors: Status:	Michael Zas	loff and Jon V	lliams	
Expiration Date: Foreign Cases:	4/25/2017 <u>Country</u> PCT PCT EPO EPO*	<u>Status</u> Filed Published Filed Issued	<u>Date</u> 4/25/97 11/6/97 4/25/97 6/11/03	<u>Serial/Patent No.</u> US97/07011 WO97/40835 97 921 396.4 0 910 382
	Japan	Filed	4/25/97	
	Japan	Published		
Austra	Australia alia Issue	Filed d 1/11/0	4/25/97)1 73588	27441/97 34
	Canada	Filed	4/25/97	2,252,584
*====	Canada	Issued	6/10/08	2,252,584
*EPO Countries:	AT, BE, CH/ PT, SE	LI, DE, DK, E	S, FI, FR, GB	, GR, IE, IT, LU, MC, NL,
Synopsis:	This patent of		mine in comb treatment of c	ination with cytotoxic ancer.
Our File: Patent No.: Issue Date: Serial No: Filing Date: Title: COMI Inventors: Status: Expiration Date:	6,596,712 7/22/2003 09/803,740 3/12/01 TREATMEN BINATION WI	TH OTHER A		
Foreign Cases:	<u>Country</u> PCT PCT EPO EPO EPO	<u>Status</u> Filed Published Filed Published Allowed	<u>Date</u> 9/10/99 3/23/2000 9/10/99 8/1/01 11193	<u>Serial/Patent No.</u> US99/20645 WO00/15176 99952905.0 361 1119361

Synopsis:	•	•		2000-569761 524481 64962/99 757649 2,343,133 ination with other anticancer reatment of cancer.
Our File: Patent No.: Issue Date: Serial No.: Filing Date: Title: Inventors: Status: Expiration Date:	6,143,738 11/7/2000 08/857,288 5/16/97 (pric		/95)	49-08M) DSTEROL COMPOUND
Foreign Cases:	Country PCT PCT EPO EPO Japan Japan Australia Australia Canada Canada	Status Filed Published Filed Published Abandoned Filed Published Filed Issued Filed Issued	Date 5/16/97 11/27/97 5/16/97 6/23/99 5/16/97 5/21/02 5/16/97 3/8/01 72690 5/16/97 5/13/08	Serial/Patent No. US97/08395 WO97/44044 97 926 574.1 0923377 0923377 1997542602 2002515035 31306/97 09 2,255,856 2,255,856
Synopsis:	This patent		e of trodusque	emine for appetite
Our File: Patent No.: Issue Date: Serial No.: Filing Date: Title: Inventors: Status: Expiration Date: Foreign Cases:	7,410,959 8/12/08 09/885,247 7/13/00, Pro THERAPEU		00 DR AN AMINC y, Mike McLa <u>Date</u>	OSTEROL COMPOUND ne, Mark Anderson and Jon Serial/Patent No.
	PCT PCT PCT	Published Abandoned	7/13/01 1/24/02 1/24/03	US01/22078 WO02/06299 WO02/06299

Synopsis:	This application covers the use of <i>trodusquemine</i> and <i>trodusquemine</i> analogues for the treatment of atherosclerosis by the reduction of serum cholesterol and the reduction of blood glucose.					
Our File: Serial No.: Filing Date: Publication No.: Date: Title: Inventors: Status: Foreign Cases: <i>Synopsis:</i>	12/041,440 3/3/2008 2008-02210 9/11/08 THERAPEU Michael Zas Williams Pending None This applica	ITIC USES FO loff, Bill Kinne tion covers th	5,247) DR AN AMINC y, Mike McLa e composition	DSTEROL COMPOUND ne, Mark Anderson and Jon of matter of MSI-1814 and to prevent weight gain.		
Our File: Serial No.: Filing Date: Publication No.: Date: Title: Inventors: Status: Foreign Cases: <i>Synopsis:</i>	65-03M, (36870-5062-03) 12/254,656 (Con of 09/885,247) 10/20/2008 2009-0105204-A1 4/23/2009 THERAPEUTIC USES FOR AN AMINOSTEROL COMPOUND Michael Zasloff, Bill Kinney, Mike McLane, Mark Anderson and Jon Williams Pending None This application covers the composition of matter of MSI-1814 and for its use for appetite suppression and to prevent weight gain.					
Our File: Patent No.: Issue Date: Serial No.: Filing Date: Title: Inventors: Status:	STEREÖSE COMPOUN AMINOSTE COMPOUN William A. K	visional 12/6/9 ELECTIVE SY DS USEFUL F ROLS, VITAN DS	NTHESIS OF FOR THE PRI IIN D ANALO	24-HYDROXYLATED EPARATION OF GS, AND OTHER ai Zhang, Meena Rao, Lee		
Expiration Date: Foreign Cases:	12/5/2017 <u>Country</u> PCT	<u>Status</u> Filed	<u>Date</u> 12/8/97	<u>Serial/Patent No.</u> US97/22031		

	PCT EPO	Published Abandoned	6/11/98	WO98/24800 97952256.2
07050	EPO EPO 2256.2	Filed	5/21/2003	03011093.6 div. of
97952	EPO Australia Australia Japan Canada	Published Filed Issued Filed Filed	2/18/04 12/8/97 8/15/2002 12/8/97 12/8/97	01389623 55914/98 746559 10-524012 2,272,721
Synopsis:			•	,721 hthesis of squalamine and trodusquamine.
Our File: Patent No.: Issue Date:	69-01M (502 6,933,383 8/23/05	29M (036870-	5067-03))	
Serial No.: Filing Date: Publication No.	10/268,660 cont. of 09/833,058 (60/196,646) 10/11/02 (4/12/00p) 20030171576			
Publication Date Title:		CTIVE AND G SYSTEMS		ECTIVE OXIDATION OF R THE PREPARATION OF
Inventors: Status:			Zhang and R	on Mlchalaki
Expiration Date:	4/12/2021	0		
Foreign Cases:	<u>Country</u> PCT PCT Australia	<u>Status</u> Filed Published Filed	<u>Date</u> 4/12/01 10/25/01 4/12/01	<u>Serial/Patent No.</u> US01/12004 WO01/79255 2001253427
	Australia Australia	Accepted Issued	2/8/07 20012 5/25/07	253427 2001253427
	Canada Canada	Filed Allowed	4/12/01 2/27/09	2,406,847 2,406,847
	EPO EPO	Applied Published	4/12/01 1/15/03	01 926 924.0 1274718
Japar	EPO* Filed	Issued 4/12/0	10/18/06	1274718 576852
Japai	Japan	Published	10/21/03	2003-531148
Synopsis:	This patent of short synthe	covers the cor sis route for s	mposition of n	natter of intermediates in a odusquamine or related
*EPO Countries:	<i>aminosterols</i> AT BE CH/ LI C		FR GB GR IE IT	LU MC NL PT SE TR

Our File: Patent No.: Issue Date: Serial No.: Filing Date: Publication No. Publication Date Title: Inventors:	6,610,866 8/26/2003 09/833,055, 12/7/97 (pro 2002-006883 6/6/02 STEREOSE COMPOUNI AMINOSTER COMPOUNI William A. Ki	LECTIVE SYI DS USEFUL F ROLS, VITAM DS inney, Steven	96) NTHESIS OF FOR THE PRE IIN D ANALOG Jones, Xueha	24-HYDROXYLATED EPARATION OF GS, AND OTHER ai Zhang, Meena Rao,
Status:	Issued	Iru, naroiu me	eckler, Nancy	Lee
Expiration Date:	3/22/2018			
Foreign Cases			Date	Serial/Patent No.
55914	Australia 1/98	Filed	7/29/02	2002300302, Div. of
0001-	Australia	Accepted	8/10/06	2002300302
Synopsis:		covers interm	ediates in the aminosterol c	synthesis of squalamine, ompounds
Our File: Serial No.: Filing Date: Publication No. Publication Date	69-04M (5029M (036870-5067-06)) 11/083,961(Div of 10/268,660 cont. of 09/833,058 (60/196,646)) 3/21/05 (4/12/00p) 2005-0187202 8/25/05			
Title:	REGIOSELE	G SYSTEMS		ECTIVE OXIDATION OF R THE PREPARATION OF
Inventors:	William A. Ki	inney, Xuehai	Zhang and R	on Michalaki
Status:	Pending	,	, .	
Synopsis:	•		t synthesis rol aminosterols.	ite for squalamine,
Our File: Patent No.: Issue Date: Serial No.: Filing Date: Title: Inventors: Status: Expiration Date:	AMINOSTER Meena Rao, and Michael Issued 8/12/2018	60/096,337) 2/98) (8/12/99 ROL COMPO Binyamin Fei Zasloff	UNDS AND U bush, William	ISES THEREOF Kinney, Lincoln Noecker
Foreign Cases:	<u>Country</u>	<u>Status</u>	<u>Date</u>	<u>Serial/Patent No.</u>

PCT *EPO Countries: <i>Synopsis:</i>	This patent of	Filed 2/24/00 Filed Published Issued Filed Issued Filed LI, DE, FR, G covers severa ed by other ap	l natural amin	US99/18322 99942130.8 1105407 2000-564639 2002-522501 55575/99 773038 2,339,174
Our File: Serial No.: Filing Date: Publication No.: Date: Title: Inventors:	83M (036870-5088) 11/410,098 (60/674,531) 4/25/06 (4/25/05p) 2007/0010504 1/11/2007 POLYMORPHIC AND AMORPHOUS SALT FORMS OF SQUALAMINE DILACTATE Eric Chellquist, Mary Doubleday, Charles Gilbert, Xuehai Zhang, Michael McLane, Kyle Armbruster and Roy C. Levitt			
Status: Foreign Cases:	Pending <u>Country</u> PCT PCT Australia Canada EPO Japan Japan	<u>Status</u> Filed Published Filed Filed Filed Filed Published	Date 4/25/06 11/2/06 4/25/06 4/25/06 4/25/06 11/13/08	Serial/Patent No. US2006/015468 WO/2006116309 2006239811 2,606,077 1877419 2008-509005 2008-539243
		Filed		
Synopsis:	polymorphic		4/25/06 vers the comp ous salt forms	095114792 Dosition of matter of of squalamine dilactate and

Foreign Cases:	<u>Country</u> PCT PCT Australia Canada China Japan Mexico Taiwan	<u>Status</u> Filed Published Filed Filed Filed Filed Filed Filed	Date 4/23/07 11/1/07 4/23/07 4/23/07 4/23/07 4/23/07 4/23/07 4/23/07	<u>Serial/Patent No.</u> US2007/009706 WO2007/124086 2007240652 200780022423.1 MX/a/2008/013592 096114648
Synopsis:	This patent a treatment of mechanism	application co diet-induced of trodusquen	vers the us obesity and nine for the	e of trodusquemine for the l associated complications and treatment of obesity and TP1B and DAT/NET.
Our File: Serial No.: Filing Date: Title: Inventors: Status:)7) FOR TREATI		TES Henry R. Wolfe
Foreign Cases: Synopsis:	<u>Country</u> PCT Taiwan This patent a			